NASDAQ:PSTV

Plus Therapeutics Earnings Date, Estimates & History

$1.93
-0.01 (-0.52 %)
(As of 08/4/2021 04:47 PM ET)
Add
Compare
Today's Range
$1.82
$1.94
50-Day Range
$1.84
$2.89
52-Week Range
$1.79
$5.42
Volume235,254 shs
Average Volume941,036 shs
Market Capitalization$40.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.36

Plus Therapeutics (NASDAQ:PSTV) Earnings Information

Plus Therapeutics last issued its earnings results on July 22nd, 2021. The reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02. Plus Therapeutics has generated ($1.86) earnings per share over the last year (($1.70) diluted earnings per share). Earnings for Plus Therapeutics are expected to decrease in the coming year, from ($0.98) to ($0.99) per share. Plus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 28th, 2021 based off prior year's report dates.

Plus Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Plus Therapeutics (NASDAQ:PSTV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.98 EPS
Next Year EPS Consensus Estimate: $-0.99 EPS

Plus Therapeutics (NASDAQ PSTV) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
10/28/2021
(Estimated)
        
7/22/20216/30/2021($0.23)($0.25)($0.02)($0.25)    
4/22/20213/31/2021($0.31)($0.33)($0.02)($0.33)  
2/22/2021Q4 2020($0.33)($0.73)($0.40)($0.73)
10/22/20209/30/2020($6.38)($0.39)+$5.99($0.39)  
8/10/20206/30/2020($0.75)($0.45)+$0.30($0.45)$0.19 million  
5/14/20203/31/2020($0.75)($0.28)+$0.47($0.28)$0.12 million  
3/30/202012/31/2019($0.66)$0.23+$0.89$0.13$1.20 million  
11/14/2019Q3($5.85)($0.03)+$5.82($0.03)$4.77 million  
8/15/2019Q2($9.75)($5.12)+$4.63$10.43$0.30 million
5/14/2019Q1 2019($9.00)($9.00)($9.00)$0.70 million
4/1/2019Q4 2018($10.00)($10.00)($12.00)$1.10 million
11/14/2018Q3 2018($6.50)($22.50)($16.00)($17.50)$3.24 million$1.31 million
8/14/2018Q2 2018($24.50)($29.50)($5.00)($29.50)$2.50 million$1.56 million
5/10/2018Q1 2018($20.00)($35.00)($15.00)($35.00)$2.43 million$0.73 million
3/8/2018Q4 2017($50.00)($50.00)$2.00 million$1.50 million
11/9/2017Q3 2017($80.00)($70.00)+$10.00($70.00)$2.04 million$1.77 million
8/10/2017Q2 2017($80.00)($90.00)($10.00)($85.00)$2.15 million$1.50 million
5/11/2017Q1 2017($135.00)($130.00)+$5.00($95.00)$3.12 million$1.61 million
3/23/2017Q4 2016($130.00)($120.00)+$10.00($120.00)$2.98 million$1.47 million
11/9/2016Q3 2016($235.00)($130.00)+$105.00($130.00)$0.73 million
8/4/2016Q2 2016($245.00)($215.00)+$30.00($215.00)$2.93 million$1.13 million
5/10/2016Q1 2016($3,073.46)($3,073.46)($3,073.46)$2.92 million
3/3/2016Q4 2015($299.85)($224.89)+$74.96($299.85)$2.90 million$1.56 million
11/5/2015Q3 2015($449.78)($299.85)+$149.93($674.66)$0.77 million
8/6/2015Q2 2015($74.96)($224.89)($149.93)($674.67)$2.78 million$1.61 million
5/11/2015Q1 2015($599.70)($524.74)+$74.96$524.73$2.57 million$2.35 million
3/12/2015Q4 2014($824.59)($599.70)+$224.89($599.70)$1.95 million$3.77 million
11/6/2014Q3 2014($674.66)($899.55)($224.89)($899.55)$4.31 million$1.10 million
8/11/2014Q2 2014($824.59)($1,124.44)($299.85)($1,124.44)$2.76 million$0.94 million
5/12/2014Q1 2014($974.51)($1,049.48)($74.97)($1,049.48)$3.42 million$1.03 million
3/11/2014Q4 2013($899.55)($1,049.48)($149.93)($1,049.48)$3.25 million$2.71 million
11/7/2013Q3 2013($824.59)($599.70)+$224.89($599.70)$2.97 million$1.62 million
8/8/2013Q2 2013($974.51)($899.55)+$74.96($1,424.29)$2.52 million$1.41 million
5/9/2013Q1 2013($1,199.40)($824.59)+$374.81($824.59)$3.24 million$1.39 million
(Earnings results data provided by Zacks Investment Research)
speech bubbles
speech bubbles











Plus Therapeutics (NASDAQ:PSTV) Earnings Frequently Asked Questions

When will Plus Therapeutics announce their next quarterly earnings?

Plus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 28th, 2021 based off last year's report dates. Learn more on PSTV's earnings history

When did Plus Therapeutics announce their last quarterly earnings?

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earning data on Thursday, July 22, 2021. Learn more on PSTV's earnings history

Did Plus Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Plus Therapeutics (NASDAQ:PSTV) missed the analysts' consensus estimate of ($0.23) by $0.02 with a reported earnings per share (EPS) of ($0.25). Learn more on PSTV's earnings details

How can I listen to Plus Therapeutics's earnings conference call?

The conference call for Plus Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Plus Therapeutics's conference call transcript?

The conference call transcript for Plus Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Plus Therapeutics generate each year?

Plus Therapeutics (NASDAQ:PSTV) has a recorded annual revenue of $300,000.00.

How much profit does Plus Therapeutics generate each year?

Plus Therapeutics (NASDAQ:PSTV) has a recorded net income of -$8.24 million. PSTV has generated -$1.86 earnings per share over the last four quarters.

What is Plus Therapeutics's EPS forecast for next year?

Plus Therapeutics's earnings are expected to decrease from ($0.98) per share to ($0.99) per share in the next year.

This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.